How is it different from regular interferon beta-1a?

Pegylation attaches a polyethylene-glycol molecule that lengthens the drug's half-life, so it can be dosed once every two weeks instead of more frequently, while retaining the immunomodulatory effects of interferon beta.

How well does it work?

In the phase 3 ADVANCE trial it significantly reduced the annualized relapse rate versus placebo, with two-year data and MRI outcomes supporting sustained benefit. Like all interferon-beta therapies, it is a moderately effective disease-modifying option.

What are the main side effects?

Injection-site reactions and flu-like symptoms (fever, chills, muscle aches, fatigue) are the most common, especially early on. Liver-enzyme elevations, depression, and reduced blood counts can also occur and require periodic monitoring.

Can I use it without a neurologist?

No. It is a prescription injectable biologic that must be prescribed, titrated, and monitored by a physician, typically a neurologist, with periodic blood tests. It is not a self-directed or over-the-counter treatment.

EMA-approvedaka Plegridy

Peginterferon beta-1a — Complete Research Guide (2026)

Last updated 2026-06-30

TL;DR

Peginterferon beta-1a (also known as Plegridy) is a peptide catalogued under Immune (PEG-IFN-β). Neutral reference entry; EU status: EU-approved prescription medicine.

What is Peginterferon beta-1a?

Peginterferon beta-1a (brand name Plegridy) is a pegylated form of interferon beta-1a, in which a polyethylene-glycol molecule is attached to extend the drug's half-life and allow less frequent dosing. It received FDA approval in 2014 for relapsing forms of multiple sclerosis (MS).

Its approval is based on the phase 3 ADVANCE randomized controlled trial and supporting MRI and long-term extension data. It is an established, specialist-prescribed disease-modifying therapy, not an experimental or over-the-counter product.

How does Peginterferon beta-1a work?

Interferon beta binds the type I interferon receptor and modulates immune activity, reducing pro-inflammatory cytokines, limiting T-cell migration across the blood-brain barrier, and dampening the inflammatory processes that drive MS relapses.

Pegylation prolongs exposure so the drug can be given every two weeks rather than more frequently.

What does the research say about Peginterferon beta-1a?

Reduces the annualized relapse rate versus placebo in relapsing-remitting MS in the pivotal phase 3 ADVANCE trial. ^[1]
Sustains reduced relapse rates and disability progression over two years of treatment in ADVANCE. ^[2]
Lowers MRI lesion activity and increases the proportion of patients achieving no evidence of disease activity (NEDA). ^[3]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

[1] Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study — Calabresi PA et al., Lancet Neurology 2014. (Randomized controlled trial, phase 3)
[2] Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE — Kieseier BC et al., Multiple Sclerosis Journal 2015. (Randomized controlled trial, extension)
[3] Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis — Arnold DL et al., BMC Neurology 2014. (Randomized controlled trial)
[4] Long-term outcomes of peginterferon beta-1a in multiple sclerosis: results from the ADVANCE extension study, ATTAIN — Newsome SD et al., Therapeutic Advances in Neurological Disorders 2018. (Extension study, long-term follow-up)
[5] PEGylated IFN beta-1a in the treatment of multiple sclerosis — Khan UT et al., Expert Opinion on Biological Therapy 2015. (Review)

Dosing context

This is not medical advice or a usage recommendation. Dosing figures are reported research context only, cited from the published literature.

In clinical use Plegridy is given by subcutaneous injection once every two weeks after an initial dose-titration period to reduce flu-like symptoms, and an intramuscular formulation was later introduced.

This is contextual information only, not a dosing recommendation; the drug is prescribed and titrated under neurologist supervision.

Side effects & safety profile

The most common adverse effects are injection-site reactions (redness, pain, itching) and a flu-like syndrome (fever, chills, muscle aches, fatigue), which is frequent early in treatment and often mitigated with dose titration and antipyretics.

Hepatic effects (elevated transaminases and, rarely, serious liver injury), depression and other neuropsychiatric symptoms, decreased blood counts, and hypersensitivity reactions can occur and warrant monitoring.

It does not carry the interferon-alpha class boxed warning, but it remains a prescription biologic requiring physician oversight and periodic laboratory testing.

Stacking & combinations

As a disease-modifying MS therapy it is used as monotherapy and is not intended to be combined with other MS immunomodulators outside of specialist-directed treatment plans.

Finding Peginterferon beta-1a vendors

This is an independent, neutral directory — we sell nothing and route no purchases. Use it to read regulatory context and (where available) genuine, moderated vendor information for your country.

Choose your country

We never list placeholder vendors. Pick your country to see neutral regulatory context.

Browse the directory

User reviews

No reviews yet

Reviews appear here once submitted and moderated. An aggregate rating is shown only after at least 5 genuine reviews — we never fabricate ratings.

Frequently asked questions

It is FDA-approved (2014) under the brand name Plegridy for relapsing forms of multiple sclerosis. It is a disease-modifying therapy intended to reduce relapses and slow disability accumulation.

References

[1] Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study — Calabresi PA et al., Lancet Neurology 2014. PMID: 24794721. View sourceStudy: Randomized controlled trial, phase 3Peginterferon beta-1a every 2 weeks significantly reduced the annualized relapse rate versus placebo at one year in relapsing-remitting MS.
[2] Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE — Kieseier BC et al., Multiple Sclerosis Journal 2015. PMID: 25432952. View sourceStudy: Randomized controlled trial, extensionTwo-year ADVANCE data confirmed sustained reductions in relapse rate and disability progression with every-2-week dosing.
[3] Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis — Arnold DL et al., BMC Neurology 2014. PMID: 25551571. View sourceStudy: Randomized controlled trialPeginterferon beta-1a reduced MRI lesion activity and increased the proportion of patients achieving no evidence of disease activity.
[4] Long-term outcomes of peginterferon beta-1a in multiple sclerosis: results from the ADVANCE extension study, ATTAIN — Newsome SD et al., Therapeutic Advances in Neurological Disorders 2018. PMID: 30181778. View sourceStudy: Extension study, long-term follow-upLong-term ATTAIN follow-up showed maintained efficacy and a consistent safety profile over up to several years of treatment.
[5] PEGylated IFN beta-1a in the treatment of multiple sclerosis — Khan UT et al., Expert Opinion on Biological Therapy 2015. PMID: 26036950. View sourceStudy: ReviewReviewed the pharmacology, efficacy, and every-2-week dosing advantage of PEGylated interferon beta-1a for relapsing MS.

This article is for educational and research purposes only. Peptides discussed here are not approved for human consumption by the FDA, EMA, or equivalent regulators outside of specific clinical contexts. Always consult a licensed medical professional before any therapeutic use.